In October 2020, a 33-year-old male from Europe, received a disheartening diagnosis – glioblastoma multiforme (GBM). His medical journey began with a comprehensive imaging session that revealed the presence of a malignant tumor. Facing the aggressive nature of GBM, he underwent a rigorous treatment in the hospital. In the aftermath of his second surgery to address residual tumor growth, he embarked on a combination therapy consisting of temozolomide (150mg/m2/day for 5 days per month) and bevacizumab (10mg/m2 administered twice a month).
2020年十月，一名来自欧洲的33岁男性接受了令人沮丧的诊断 - 胶质母细胞瘤（GBM）。他的医学之旅始于一次全面的影像检查，揭示了一个恶性肿瘤的存在。面对GBM的侵袭性本质，他在医院接受了严格的治疗。在第二次手术处理残留肿瘤生长后，他开始了一种联合疗法，包括替莫唑胺（每月5天，每天150毫克/平方米）和贝伐单抗（每月两次，每次10毫克/平方米）。
This regimen sustained him for an entire year until October 2021, when a subsequent imaging session disclosed disease progression despite the prolonged treatment. Undeterred, His medical team explored alternative treatment for Glioblastoma. They decided to introduce a novel approach to his treatment – ECCT, a novel treatment that uses electric field and non-invasive device. He started ECCT which administered five days a week with 15-120 minutes, twice a day. At the same time, his medical team continued to prescribe him with Bevacizumab, hoping that with electric field potential, it enhance the membrane potential to enhance delivery of the medication that did not respond earlier to work it's way into the tumor cells.
这个疗程维持了整整一年，直到2021年10月，当时一次随后的影像检查显示尽管治疗时间较长，疾病仍在进展。尽管如此，他的医疗团队并未气馁。他们决定尝试替代疗法，引入一种新的治疗方法 - ECCT，这是一种利用电场和非侵入性设备的新型治疗。他开始接受ECCT，每周五次，每次15-120分钟，每天两次。同时，他的医疗团队继续为他开处方贝伐单抗，希望通过电场的电位增强细胞膜电位，提高药物传递效果，使之前未能起效的药物能够更好地进入肿瘤细胞。
Miraculously, after just two months of the ECCT protocol combined with bevacizumab, he experienced a remarkable improvement. The follow-up imaging above showcased an almost complete response to the treatment. Encouraged by this promising development, the medical team continued the therapy.
神奇的是，在仅仅两个月的ECCT协议与贝伐单抗联合治疗后，他经历了显著的改善。上述的随访影像展示了对治疗的几乎完全的反应。受到这一令人鼓舞的发展的鼓舞，医疗团队继续进行治疗。
In a stunning turn of events, after four months of ECCT accompanied by bevacizumab, the subsequent imaging session unveiled a complete response. He, once faced with the grim reality of glioblastoma, emerged victorious over the relentless disease. His journey stands as a testament to the potential of innovative treatments and the unwavering spirit of those determined to conquer adversity.
在一场惊人的变故中，经过四个月的ECCT联合贝伐单抗治疗后，随后的影像检查揭示出了完全的反应。曾经面临着胶质母细胞瘤严酷现实的他，最终战胜了这不屈不挠的疾病。他的旅程成为对创新治疗潜力和那些决心战胜逆境的人坚定精神的明证。He wishes to convey a message to all cancer warriors out there: the utilization of electric field therapy in oncology has been a fundamental component of safe and supportive protocols for glioblastoma in Western countries for over a decade. In recent years, this innovative approach has started to find its way into Asian countries. While it might take some time for electric field treatment to be fully integrated into traditional practices, the positive advancements in Western oncology serve as a beacon of hope. As awareness expands and success stories, such as his own, continue to emerge, the potential for wider acceptance and adoption of electric field therapy in the realm of cancer treatment becomes increasingly promising. The journey towards acceptance is in progress, and the positive impact on patients' lives could pave the way for its acknowledgment in traditional treatment paradigms. Therefore, he hopes that all cancer warriors do not lose hope during their journey, as you never know what might work until you give it a try.
他希望向所有癌症战士传达一个信息：电场疗法在肿瘤学中已经成为西方国家治疗胶质母细胞瘤安全而支持性协议的基本组成部分已有十多年。近年来，这种创新方法已经开始进入亚洲国家。虽然电场治疗可能需要一些时间才能完全融入传统实践，但在西方肿瘤学取得的积极进展是一束希望的光芒。随着认知的扩大和像他这样的成功案例不断涌现，电场疗法在癌症治疗领域更广泛接受和采用的潜力变得越来越有希望。接受的征程正在进行中，对患者生活的积极影响可能为其在传统治疗范式中的认可铺平道路。因此，他希望所有癌症战士在旅程中不要失去任何希望，因为在尝试之前，你永远不知道哪种方法会奏效。
Comments